Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,293,176
  • Shares Outstanding, K 960,131
  • Annual Sales, $ 24,556 M
  • Annual Income, $ 3,232 M
  • 60-Month Beta 0.16
  • Price/Sales 4.42
  • Price/Cash Flow 16.30
  • Price/Book 31.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.51
  • Number of Estimates 3
  • High Estimate 1.53
  • Low Estimate 1.48
  • Prior Year 1.33
  • Growth Rate Est. (year over year) +13.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.36 +9.90%
on 10/23/19
114.67 -2.86%
on 10/31/19
+3.49 (+3.23%)
since 10/14/19
3-Month
101.36 +9.90%
on 10/23/19
117.23 -4.98%
on 09/20/19
+1.10 (+1.00%)
since 08/14/19
52-Week
101.36 +9.90%
on 10/23/19
132.13 -15.70%
on 03/26/19
+1.58 (+1.44%)
since 11/14/18

Most Recent Stories

More News
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

MRK : 84.55 (-0.32%)
BMY : 58.51 (-0.48%)
LLY : 111.39 (-1.24%)
CLDX : 2.27 (-2.58%)
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

MRK : 84.55 (-0.32%)
NVO : 57.89 (+0.43%)
LLY : 111.39 (-1.24%)
JNJ : 130.96 (-0.24%)
AC Immune to Present at Jefferies 2019 London Healthcare Conference

AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced that it will present at Jefferies 2019 London...

LLY : 111.39 (-1.24%)
ACIU : 6.87 (+5.21%)
Post-operative Pain Management Market 2019- Statistics Share, Growth, Industry Size, Future Trends, Segmentation, Gross Margin, Opportunities, Demand, Global Forecast to 2023

BAX : 80.74 (-0.17%)
LLY : 111.39 (-1.24%)
ENDP : 4.16 (-3.03%)
GSK : 43.85 (-1.81%)
TEVA : 9.37 (-4.19%)
VRX.TO : 30.80 (-3.33%)
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval...

LLY : 111.39 (-1.24%)
Avidity Biosciences Completes $100 Million Series C Financing

Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs(TM)) for the treatment of rare muscle disorders and other serious diseases, announced the completion of...

LLY : 111.39 (-1.24%)
% Return Seen to Date on SmarTrend Eli Lilly & Co Call (LLY)

SmarTrend identified a Downtrend for Eli Lilly & Co (NYSE:LLY) on October 2nd, 2019 at $108.65. In approximately 1 month, Eli Lilly & Co has returned 4.16% as of today's recent price of $113.17.

LLY : 111.39 (-1.24%)
Global Veterinary Antibiotics Markets, 2015-2019 and 2030 Forecast - Featuring Profiles on Major Players Bayer, Boehringer Ingelheim, Ceva Sante Animale, Eli Lilly Company and Elanco - ResearchAndMarkets.com

The "Veterinary Antibiotics Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

LLY : 111.39 (-1.24%)
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study will...

LLY : 111.39 (-1.24%)
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis

Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus Humira® (adalimumab) in biologic-naïve patients...

LLY : 111.39 (-1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 112.94
1st Resistance Point 112.17
Last Price 111.39
1st Support Level 110.81
2nd Support Level 110.22

See More

52-Week High 132.13
Fibonacci 61.8% 120.38
Fibonacci 50% 116.75
Fibonacci 38.2% 113.11
Last Price 111.39
52-Week Low 101.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar